2024
Deep learning for oncologic treatment outcomes and endpoints evaluation from CT scans in liver cancer
Xia Y, Zhou J, Xun X, Johnston L, Wei T, Gao R, Zhang Y, Reddy B, Liu C, Kim G, Zhang J, Zhao S, Yu Z. Deep learning for oncologic treatment outcomes and endpoints evaluation from CT scans in liver cancer. Npj Precision Oncology 2024, 8: 263. PMID: 39551847, PMCID: PMC11570623, DOI: 10.1038/s41698-024-00754-z.Peer-Reviewed Original ResearchProgression-free survivalCT scanLiver cancerAccurate treatment response assessmentResponse evaluationMetastatic organ sitesOncological treatment outcomesResponse Evaluation CriteriaLow-risk patientsTreatment response assessmentTreatment response evaluationTreatment response classificationAdvanced liver cancerStratify high-riskMultifocal hepatic lesionsTreatment outcome assessmentEvaluation of responseOverall survivalEvaluation CriteriaInternal five-fold cross-validationOncology clinical trialsResponse assessmentSolid tumorsClinical trialsTreatment outcomes
2023
A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies
Chee C, Ooi M, Lee S, Sundar R, Heong V, Yong W, Ng C, Wong A, Lim J, Tan D, Soo R, Tan J, Yang S, Thura M, Al-Aidaroos A, Chng W, Zeng Q, Goh B. A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies. Targeted Oncology 2023, 18: 391-402. PMID: 37060431, PMCID: PMC10192144, DOI: 10.1007/s11523-023-00962-w.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAdvanced solid tumorsFirst-in-human studyEuropean Leukemia NetworkSolid tumorsHematologic malignanciesTreatment-emergent adverse eventsHuman antibodiesDose-escalation cohortsDose-limiting toxicityGrade 2 vomitingPRL-3Refractory solid tumorsResponse Evaluation CriteriaSolid tumor patientsDose-expansion cohortReduced tumor growthFirst-in-humanPhase IStable diseaseStoma outputEvaluation CriteriaMyeloid leukemiaPharmacodynamic relationshipsAdverse events
2022
New perspectives in unresectable cholangiocarcinoma? Evaluation of chemosaturation with percutaneous hepatic perfusion as a palliative treatment option
Dewald C, Becker L, Meine T, Maschke S, Wacker F, Saborowski A, Vogel A, Hinrichs J. New perspectives in unresectable cholangiocarcinoma? Evaluation of chemosaturation with percutaneous hepatic perfusion as a palliative treatment option. Clinical & Experimental Metastasis 2022, 40: 95-104. PMID: 36417096, PMCID: PMC9898387, DOI: 10.1007/s10585-022-10193-4.Peer-Reviewed Original ResearchConceptsPercutaneous hepatic perfusionDisease control rateMedian overall survivalOverall response rateUnresectable cholangiocarcinomaHepatic perfusionAdverse eventsCommon Terminology Criteria for Adverse EventsGrade 3/4 thrombopeniaProgression-free survivalResponse Evaluation CriteriaHigh dose chemotherapyPalliative treatment optionReduced systemic exposureIncrease of transaminasesNo significant complicationsPrimary liver tumorsLiver synthesis capacityKaplan-Meier estimatesTransient hematotoxicityDose chemotherapySalvage treatmentOverall survivalDismal prognosisEvaluation Criteria
2020
Two-dimensional parametric parenchymal blood flow in transarterial chemoembolisation for hepatocellular carcinoma: perfusion change quantification and tumour response prediction at 3 months post-intervention
Becker L, Maschke S, Dewald C, Meine T, Winther H, Kirstein M, Kloeckner R, Meyer B, Wacker F, Hinrichs J. Two-dimensional parametric parenchymal blood flow in transarterial chemoembolisation for hepatocellular carcinoma: perfusion change quantification and tumour response prediction at 3 months post-intervention. Clinical Radiology 2020, 76: 160.e27-160.e33. PMID: 33028487, DOI: 10.1016/j.crad.2020.09.012.Peer-Reviewed Original ResearchConceptsArea under the curveWash-in rateDEB-TACETumor responseDigital subtraction angiographyHepatocellular carcinomaPerfusion changesTransarterial chemoembolisationModified Response Evaluation CriteriaQuantify perfusion changesTarget lesion sizeAssessment of perfusion changesResponse Evaluation CriteriaUnresectable hepatocellular carcinomaDrug-eluting beadsAcquired digital subtraction angiographyTime-attenuation curvesParenchymal blood flowTumor response predictionTime-density curvesWilcoxon signed-rank testEvaluation CriteriaSigned-rank testSolid tumorsSubtraction angiography
2017
O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors
Raj N, Klimstra D, Horvat N, Zhang L, Chou J, Capanu M, Basturk O, Gian R, Allen P, Reidy-Lagunes D. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. Pancreas 2017, 46: 758-763. PMID: 28609363, PMCID: PMC5509357, DOI: 10.1097/mpa.0000000000000842.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic Agents, AlkylatingBiomarkers, TumorCell DifferentiationChildDacarbazineDatabases, FactualDisease ProgressionDNA MethylationDNA Modification MethylasesDNA Repair EnzymesDrug Resistance, NeoplasmFemaleHumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedNeoplasm GradingNeuroendocrine TumorsPancreatic NeoplasmsPharmacogeneticsPromoter Regions, GeneticSequence Analysis, DNATemozolomideTime FactorsTreatment OutcomeTumor Suppressor ProteinsYoung AdultConceptsPancreatic neuroendocrine tumorsProgression of diseaseWD-panNETsStable diseasePartial responseNeuroendocrine tumorsAlkylating agentsAlkylating agent therapyResponse Evaluation CriteriaResistance to alkylating agentsMGMT deficiencyAgent therapyEvaluation CriteriaSolid tumorsMGMTTumorGlioblastoma multiformePanNETsPatientsDiseaseDecreased activityDNA methyltransferasesAgentsRECISTStatusRepresentation of peritoneal metastases in published clinical trials of metastatic colorectal cancer.
Tseng J, Bryan D, Poli E, Sharma M, Polite B, Turaga K. Representation of peritoneal metastases in published clinical trials of metastatic colorectal cancer. Journal Of Clinical Oncology 2017, 35: 725-725. DOI: 10.1200/jco.2017.35.4_suppl.725.Peer-Reviewed Original ResearchMetastatic colorectal cancerPeritoneal metastasisPublished Clinical TrialsClinical trialsColorectal cancerPeritoneal diseaseDetection of peritoneal metastasesMetastatic colorectal cancer patientsTrials of systemic chemotherapyModified World Health OrganizationClinical trials of metastatic colorectal cancerResponse Evaluation CriteriaWorld Health OrganizationResponse to therapyColorectal cancer patientsMeasure burden of diseaseRandomized Controlled TrialsSystemic chemotherapyEvaluation CriteriaSpecific outcomesSolid tumorsBurden of diseaseMetastasisCancer patientsPubMed search
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply